Diafiltration pH Drift: Why Your Bioprocess Buffers Aren't Behaving
"Uncover the hidden causes of pH variations during diafiltration and how to control them for stable biopharmaceutical formulations."
Diafiltration is a critical process in the production of biopharmaceuticals, serving as the final step in formulation by facilitating buffer exchange. In this process, it's common to use a constant volume to precisely control the concentrations of retained solutes. However, achieving consistent pH levels throughout diafiltration can be surprisingly challenging. Recent studies have shown that even when the initial feed and diafiltration buffers are set to the same pH, variations can arise during the process, which can lead to instability of the final formulated product.
Traditionally, these pH shifts have been attributed to interactions between buffer species and the protein product. However, there's growing evidence that the reasons can be largely independent of protein concentration, particularly in the early stages of diafiltration. The key lies in understanding the non-ideal behavior of buffer solutions, which is influenced by factors such as ionic strength. These unexpected shifts can directly influence the quality and stability of biopharmaceutical products.
This article aims to help uncover the critical insights into how buffer non-idealities affect pH during diafiltration. It will also explore strategies to control and minimize these variations, focusing on understanding the influence of ionic strength and optimizing buffer selection. By delving into the science behind diafiltration pH shifts, we aim to equip bioprocessing professionals with the knowledge to enhance process robustness and ensure the quality of their biopharmaceutical products.
pH Drift in Bioprocessing
Diafiltration is a cornerstone of biopharmaceutical manufacturing, yet unexpected pH shifts during the process can threaten product stability. While precise industry-wide statistics on the frequency or financial impact of pH drift events are not well consolidated in the public literature, the issue is widely recognized as a practical concern across biologics production. Because even small pH excursions can alter protein conformation, aggregation, and charge heterogeneity, understanding and mitigating diafiltration pH drift remains an active area of interest for process development scientists.
Buffer Nonidealities and pH Variations
Diafiltration utilizes a semipermeable membrane for buffer exchange, driven by diffusion or pressure, allowing control over the removal of small molecules from protein solutions. A study published in Biotechnology Progress found that pH variations during diafiltration are due to nonidealities in the acid-base equilibrium coefficient—specifically, the ionic strength dependence of the pKa. A model accounting for these nonidealities showed excellent agreement with experimental results obtained using phosphate and histidine buffers. This reveals that standard buffering assumptions break down under the changing ionic conditions inherent to diafiltration, a limitation not always captured by conventional process models.
Origins of Diafiltration Technology
Diafiltration is fundamentally a dilution process that separates components based on molecular size using micro-permeable filters, producing a purified solution by iteratively adding new buffer. Historically, discontinuous diafiltration—in which the solution is diluted with buffer and then concentrated—served as the foundational protocol, with the nomenclature for continuous operations developing later. Ultrafiltration and diafiltration (UF/DF) are now considered a core step in biologics and gene therapy process development and formulation, forming an integrated operation used for both concentration and buffer exchange.
The Science Behind the Shift: Non-Ideal Buffers and Ionic Strength
The driving force behind pH variations during diafiltration stems from the non-ideal behavior of buffer solutions. Ideal solutions assume that interactions between molecules are uniform, which isn't the case in real-world scenarios. Buffers, especially those containing multivalent ions such as phosphate and citrate, exhibit activity coefficients that deviate from unity, particularly at higher concentrations. These deviations are a direct result of electrostatic interactions and other molecular forces that influence the effective equilibrium of acid-base reactions.
- Debye-Hückel Theory: Explains how ionic strength affects ion activity.
- Activity Coefficients: Deviation from ideal behavior due to electrostatic forces.
- Impact on pKa: Changes in ionic strength modify buffer pKa, causing pH shifts.
Recent Advances in UF/DF
A March 2026 study in the Journal of Pharmaceutical Sciences investigated the clearance of 28 selected organic leachables spiked into three drug substances during ultrafiltration and diafiltration, providing the first systematic characterization of leachables removal capacity during UF/DF. The authors noted that while UF/DF has been demonstrated to clear leachables from drug substance, limited data was previously available for comprehensive assessment. Separately, a 2025 study published by the Korean Science Academy described the development of a new diafiltration device designed to improve buffer exchange performance in biopharmaceutical manufacturing, driven by the growing need to reduce purification and separation process costs.
Limitations and Open Questions
While pH drift during diafiltration is increasingly recognized, the bioprocessing community has not reached consensus on the relative importance of buffer nonidealities compared to other contributing factors such as membrane interactions, protein buffering capacity, and temperature variation. Some process developers report that standard platform conditions work adequately without explicit compensation for pKa shifts, suggesting the magnitude of the problem may be product- and buffer-dependent. The absence of large-scale, systematic failure analyses in the public literature means that the true prevalence and severity of pH drift-related batch outcomes remain incompletely characterized.
Buffer Performance Trade-offs
Comparative data on how different buffer systems behave under diafiltration conditions remain limited in the published literature, though available evidence points to meaningful differences. Phosphate and histidine buffers, for example, respond differently to the ionic strength changes that occur during diafiltration, with their respective pKa values shifting to varying degrees. Without systematic head-to-head studies across a broad range of buffer chemistries and process conditions, process scientists are left relying on case-specific experimental data rather than generalized comparative guidelines.
Strategies for Stable pH During Diafiltration
Controlling pH shifts during diafiltration requires a proactive approach that considers buffer properties and process parameters. One of the most effective strategies is to match the ionic strength of the feed and diafiltration buffers. This minimizes changes in activity coefficients and pKa, resulting in a more stable pH profile throughout the process. However, matching ionic strength isn't always practical, especially when specific formulation requirements dictate low-salt conditions.
Integrating pH Control into Process Design
The evidence gathered across recent research underscores that pH drift during diafiltration is not merely an academic curiosity but a practical process risk. Buffer nonidealities underpin the mechanism of pH variation, and models accounting for ionic strength effects on pKa values have proven predictive in laboratory settings. As biopharmaceutical processes grow more demanding, integrating robust pH monitoring and buffer selection strategies into early-stage process design is likely to become standard practice rather than an afterthought.
Toward Predictive, Digitally Integrated UF/DF
Current UF/DF process development is mostly based on an empirical approach using generic platform conditions and membranes, as highlighted in a September 2023 review in Computers & Chemical Engineering. The biopharmaceutical buffers market is accelerating innovation in buffer formulation to meet the precise pH and ionic strength control demanded by monoclonal antibodies and cell therapies. Next-generation UF/DF systems are being engineered to enable continuous manufacturing, modular design, and integrated digital platforms for higher throughput and tighter process control.
Optimizing Across Process Variables
A 2020 study on biotech diafiltration process optimization focused on Product X, where the key quality attributes—DF process pH, osmolality, and conductivity—were found to be variable across several manufacturing runs. The optimization effort centered on buffer and product initial conductivity as the primary process factors driving variability. Buffers represent the major component by volume in biopharmaceutical manufacturing, meaning that even small improvements in buffer management and selection can have outsized effects on process consistency and product quality.
From Bench to Manufacturing Floor
Sartorius case studies have demonstrated the practical impact of buffer choice on diafiltration flux rates and protein stability using the Ambr Crossflow high-throughput screening system, comparing four buffers: 10 mM sodium acetate pH 6, histidine pH 6, 10 mM sodium acetate pH 5.5, and histidine pH 5.5. In monoclonal antibody production, step 10—UF/DF—accomplishes both concentration and formulation in a single integrated operation, with the final product formulated in specific buffers such as citrate, histidine, polysorbate 80, and trehalose to maintain stability at 2–8°C for months. These real-world examples illustrate that the choice of diafiltration buffer is not merely a downstream convenience decision but a critical determinant of long-term product stability.
Another approach is to use a staged diafiltration process, where the ionic strength of the diafiltration buffer is gradually reduced over time. This can help to mitigate abrupt pH changes and provide better control over the final formulation. Additionally, the choice of buffer system can significantly impact pH stability. Some buffers, such as histidine, exhibit less sensitivity to ionic strength compared to phosphate, making them a better option for certain applications. Always consider factors like buffering capacity, compatibility with the protein, and regulatory requirements.
Finally, modeling and simulation can be invaluable tools for predicting and optimizing pH profiles during diafiltration. By incorporating non-ideal buffer behavior and ionic strength effects into the model, it's possible to identify critical process parameters and design a robust diafiltration process that minimizes pH variations and ensures product quality. Implementing these insights from research will help to help bioprocessing professionals stabilize product formulation and sustain consistent results.